1. Generics Bulletin
  2. >>Business
  3. >>Manufacturing

Fresenius Offloads Chilean Operation As It Slims Down Manufacturing

Peru’s Medifarma Snaps Up German Firm’s Sanderson Subsidiary, Including IV Plant

 
• By Dave Wallace

Fresenius Kabi has completed the divestment of its Chilean subsidiary Laboratorio Sanderson to Peru’s Medifarma, including the transfer of an IV drug facility in Santiago de Chile, as part of streamlining the German group’s manufacturing operations.

Santiago Chile on map
The divestment includes a plant in Santiago de Chile • Source: Shutterstock

Fresenius Kabi has divested its Chilean subsidiary Laboratorio Sanderson to Peru’s Medifarma, as part of efforts to streamline the German injectables giant’s manufacturing operations.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

Who’s Hired? Alvotech Appoints Strategy And Quality Chiefs

 
• By Dave Wallace

Alvotech has named two new key executives, while Biosimilars Canada has elected its 2025 leaders and the AAM has welcomed the new FDA commissioner in the US.

Sandoz And Delpharm Renew Canadian Injectables Supply Agreement For 10 Years

 
• By Dean Rudge

Along with financial backing from the Canadian government, a fresh, decade-long partnership with Sandoz Canada will allow Delpharm to carry out modernization plans for its manufacturing facility in Boucherville, securing the local supply chain for sterile injectable medicines.

Biocon Biologics Teams Up With Civica On US Insulin Production

 
• By Dave Wallace

Biocon Biologics is partnering with Civica to supply insulin aspart drug substance that will be used for final US manufacturing by Civica at its plant in Petersburg, Virginia.

Viatris Rocked By Indore US Block, With $500m Revenue Sting Anticipated In 2025

 
• By Dean Rudge

Viatris anticipates that half-a-billion dollars will disappear from its top line in 2025 on the back of the recent import alert for its oral solids facility in Indore, with much of the pain being caused by the firm’s failure to have its generic version of Revlimid exempt from the restrictions.

More from Business

Celltrion Unveils Strategy Amid Series Of Milestones

 
• By Adam Zamecnik

South Korea’s Celltrion has doubled down on its efforts in further building its pipeline, eyeing a target of 22 commercialized products by 2030 while also aiming to submit INDs for 13 novel compounds.

Samsung Rolls Out Second US Soliris Biosimilar – At 30% WAC Discount

 
• By Dean Rudge

Samsung Bioepis and Teva have provided clarity on the pricing of their Epysqli biosimilar to Soliris in the US, as the firms launched only the second rival to the rare diseases treatment.

Teva Crib Sheet Reveals Uzedy, Lenalidomide Expectations Ahead Of Q1

 
• By Dean Rudge

Teva is charting a new course under its ‘Pivot to Growth’ strategy, providing a memory aid for investors to better understand the firm’s financials going into 2025.